Neoadjuvant TQB2102 for HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive invasive breast cancer that has not spread to other parts of the body (stage T2-4, any N, M0 or any T, N1-3, M0).
- You have not received any prior cancer treatment for this breast cancer, including chemotherapy, radiation, or targeted therapy.
- You are well enough to undergo surgery and have an ECOG performance status of 0 or 1 (fully active or able to carry on all predisease activities without restriction).
- Your major organs (heart, liver, kidneys, blood) are functioning adequately as shown by blood tests.
- You are not pregnant or breastfeeding, and you agree to use effective contraception during the study and for 6 months after.
- You have no history of other cancers in the past 5 years, no active infections, no bleeding disorders, and no history of blood clots within the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
This trial tests a new HER2-targeted antibody drug (TQB2102) against standard chemotherapy in people with HER2-low breast cancer that has spread or come back. It aims to see if the new drug works better or is safer than usual chemotherapy.
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
This trial tests a new drug, TQB2102, for people with advanced bile duct cancer that has HER2 protein markers. It aims to see if the drug can help when previous treatments haven't worked.
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.